Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024

Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024
MAJESTIC-1 Study - A Subgroup Analysis of High-risk Patients | Luciano Costa, MD | EHA2024
ASCO/EHA Myeloma Updates 2024 | Claudio Cerchione, MD | EHA 2024
The Role of Combination FDG PET Plus Whole Body MRI for Staging | Claudio Cerchione, MD | EHA 2024
Epcoritamab's Impact on Treating Relapsed Follicular Lymphoma | Umberto Vitolo, MD | EHA 2024
Bispecific Antibodies and Precision Medicine Insights on Myeloma Prognosis | Ola Landgren, MD | EHA 2024
Administering Outpatient CAR T-cell Therapy in Non-Hodgkin Lymphoma | Radhika Bansal, MD | EHA 2024
Real World Outcomes of RRMM Using Kyprolis | Sharlene Dong, MD, MS | EHA 2024
Integrating BCMA-Targeted Therapies into Challenging Myeloma Cases | Rakesh Popat, PhD | EHA 2024
Treating RRMM with Bispecific Antibodies | Rakesh Popat, PhD | EHA 2024
Managing the Unique Side Effects of Talquetamab | Ajai Chari, MD | EHA 2024
LINVOSELTAMAB in Patients with Relapsed/Refractory Myeloma | Suzanne Lentzsch MD, PhD | EHA 2024
Cevostamab in RRMM Patients: CAMMA 2 Study Results | Joshua Richter, MD | EHA 2024
ASCO/EHA 2024 Myeloma Highlights - IMROZ, DREAMM-7, DREAMM-8 | Joshua Richter, MD | EHA 2024
IMROZ - IsaRVd vs RVd in Newly Diagnosed Transplant Ineligible MM | Thierry Facon, MD | EHA 2024
Frailty Adaptive Therapy in Newly Diagnosed Myeloma Patients | Maria Victoria Mateos, MD | EHA 2024